Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Nektar Therapeutics Long Term Debt 2011-2025 | NKTR

Nektar Therapeutics long term debt from 2011 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Nektar Therapeutics Annual Long Term Debt
(Millions of US $)
2024
2023
2022
2021
2020
2019
2018 $247
2017 $245
2016 $243
2015 $243
2014 $129
2013 $133
2012 $137
2011 $15
2010 $232
Nektar Therapeutics Quarterly Long Term Debt
(Millions of US $)
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $248
2019-06-30 $248
2019-03-31 $247
2018-12-31 $247
2018-09-30 $247
2018-06-30 $246
2018-03-31 $246
2017-12-31 $245
2017-09-30 $245
2017-06-30 $245
2017-03-31 $246
2016-12-31 $243
2016-09-30 $245
2016-06-30 $245
2016-03-31 $245
2015-12-31 $243
2015-09-30 $1
2015-06-30 $128
2015-03-31 $129
2014-12-31 $129
2014-09-30 $130
2014-06-30 $131
2014-03-31 $132
2013-12-31 $133
2013-09-30 $134
2013-06-30 $135
2013-03-31 $136
2012-12-31 $137
2012-09-30 $137
2012-06-30 $13
2012-03-31 $14
2011-12-31 $15
2011-09-30 $15
2011-06-30 $231
2011-03-31 $231
2010-12-31 $232
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.205B $0.098B
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $80.531B 30.59
Zoetis (ZTS) United States $52.936B 18.95
Takeda Pharmaceutical (TAK) Japan $44.579B 9.10
Daiichi Sankyo, - (DSNKY) Japan $41.884B 20.86
BeOne Medicines - (ONC) Switzerland $37.686B 199.80
Sandoz Group AG (SDZNY) Switzerland $30.065B 0.00
United Therapeutics (UTHR) United States $19.772B 17.40
Merck (MKKGY) Germany $16.918B 11.00
Summit Therapeutics (SMMT) United States $14.775B 0.00
Neurocrine Biosciences (NBIX) United States $14.686B 35.24
Shionogi (SGIOY) Japan $14.581B 13.39
IPSEN (IPSEY) France $12.599B 0.00
Madrigal Pharmaceuticals (MDGL) United States $12.298B 0.00
Ionis Pharmaceuticals (IONS) United States $11.735B 0.00
Orion OYJ (ORINY) Finland $9.625B 27.50
Corcept Therapeutics (CORT) United States $8.311B 89.78
Eisai (ESAIY) $8.236B 0.00
Stevanato Group S.p.A (STVN) Italy $7.320B 40.97
Grifols, S.A (GRFS) Spain $6.002B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.204B 15.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.586B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $4.493B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.075B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.753B 17.84
Hypermarcas (HYPMY) Brazil $3.123B 23.48
Centessa Pharmaceuticals (CNTA) United Kingdom $3.018B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.839B 9.06
Dyne Therapeutics (DYN) United States $2.809B 0.00
Soleno Therapeutics (SLNO) United States $2.616B 0.00
Ocular Therapeutix (OCUL) United States $2.390B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.067B 24.50
Guardian Pharmacy Services (GRDN) United States $1.979B 38.11
Avadel Pharmaceuticals (AVDL) Ireland $1.828B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.522B 90.38
Ardelyx (ARDX) United States $1.489B 0.00
Harrow (HROW) United States $1.435B 88.04
Collegium Pharmaceutical (COLL) United States $1.417B 7.02
Amylyx Pharmaceuticals (AMLX) United States $1.393B 0.00
Xeris Biopharma Holdings (XERS) United States $1.234B 0.00
Oruka Therapeutics (ORKA) United States $1.171B 0.00
Enliven Therapeutics (ELVN) United States $1.163B 0.00
Relay Therapeutics (RLAY) United States $1.090B 0.00
Xencor (XNCR) United States $1.062B 0.00
Evotec AG (EVO) Germany $1.055B 0.00
Cronos Group (CRON) Canada $0.965B 0.00
Theravance Biopharma (TBPH) United States $0.932B 39.36
ARS Pharmaceuticals (SPRY) United States $0.867B 0.00
Organogenesis (ORGO) United States $0.825B 0.00
ProKidney (PROK) United States $0.824B 0.00
Savara (SVRA) United States $0.748B 0.00
Esperion Therapeutics (ESPR) United States $0.741B 0.00
Aquestive Therapeutics (AQST) United States $0.694B 0.00
Elite Pharmaceuticals (ELTP) United States $0.694B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.689B 6.15
Bioventus (BVS) United States $0.637B 13.05
4D Molecular Therapeutics (FDMT) United States $0.617B 0.00
KalVista Pharmaceuticals (KALV) United States $0.580B 0.00
Zevra Therapeutics (ZVRA) United States $0.531B 0.00
Lexeo Therapeutics (LXEO) United States $0.492B 0.00
Akebia Therapeutics (AKBA) United States $0.480B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.469B 11.11
Siga Technologies (SIGA) United States $0.450B 6.17
Altimmune (ALT) United States $0.447B 0.00
Galectin Therapeutics (GALT) United States $0.355B 0.00
Nature's Sunshine Products (NATR) United States $0.350B 20.83
USANA Health Sciences (USNA) United States $0.348B 9.70
Lyell Immunopharma (LYEL) United States $0.331B 0.00
Aldeyra Therapeutics (ALDX) United States $0.315B 0.00
Korro Bio (KRRO) United States $0.308B 0.00
Larimar Therapeutics (LRMR) United States $0.300B 0.00
Pyxis Oncology (PYXS) United States $0.285B 0.00
Achieve Life Sciences (ACHV) Canada $0.254B 0.00
Aclaris Therapeutics (ACRS) United States $0.249B 0.00
Journey Medical (DERM) United States $0.238B 0.00
OmniAb (OABI) United States $0.232B 0.00
Heron Therapeutics (HRTX) United States $0.213B 0.00
AleAnna (ANNA) United States $0.210B 0.00
Protara Therapeutics (TARA) United States $0.207B 0.00
MediWound (MDWD) Israel $0.205B 0.00
Avalo Therapeutics (AVTX) United States $0.204B 0.00
Profound Medical (PROF) Canada $0.194B 0.00
Innate Pharma SA (IPHYF) France $0.168B 0.00
China SXT Pharmaceuticals (SXTC) China $0.161B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.154B 0.00
Cassava Sciences (SAVA) United States $0.150B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.128B 0.00
Incannex Healthcare (IXHL) Australia $0.125B 0.00
Inhibikase Therapeutics (IKT) United States $0.122B 0.00
Avita Medical (RCEL) United States $0.121B 0.00
Context Therapeutics (CNTX) United States $0.109B 0.00
Relmada Therapeutics (RLMD) United States $0.109B 0.00
Surrozen (SRZN) United States $0.104B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
Gain Therapeutics (GANX) United States $0.097B 0.00
Champions Oncology (CSBR) United States $0.096B 35.00
Karyopharm Therapeutics (KPTI) United States $0.093B 0.00
Vivani Medical (VANI) United States $0.090B 0.00
Assertio Holdings (ASRT) United States $0.089B 0.00
Dominari Holdings (DOMH) United States $0.087B 0.00
VAXART, INC (VXRT) United States $0.085B 0.00
Unicycive Therapeutics (UNCY) United States $0.085B 0.00
Metagenomi (MGX) United States $0.083B 0.00
Plus Therapeutics (PSTV) United States $0.078B 0.00
Prelude Therapeutics (PRLD) United States $0.076B 0.00
Lite Strategy (LITS) United States $0.074B 0.00
Nutriband (NTRB) United States $0.073B 0.00
PMV Pharmaceuticals (PMVP) United States $0.070B 0.00
Rafael Holdings (RFL) United States $0.066B 0.00
Acrivon Therapeutics (ACRV) United States $0.065B 0.00
BioNxt Solutions (BNXTF) Canada $0.063B 0.00
Talphera (TLPH) United States $0.060B 0.00
PolyPid (PYPD) Israel $0.060B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.058B 0.00
Fractyl Health (GUTS) United States $0.055B 0.00
Wellgistics Health (WGRX) United States $0.053B 0.00
ElectroCore (ECOR) United States $0.050B 0.00
Arch Biopartners (ACHFF) Canada $0.050B 0.00
NRx Pharmaceuticals (NRXP) United States $0.049B 0.00
Telomir Pharmaceuticals (TELO) United States $0.049B 0.00
Century Therapeutics (IPSC) United States $0.049B 0.00
Jupiter Neurosciences (JUNS) United States $0.046B 0.00
Tempest Therapeutics (TPST) United States $0.043B 0.00
FibroGen (FGEN) United States $0.040B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.039B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
Inotiv (NOTV) United States $0.036B 0.00
Klotho Neurosciences (KLTO) United States $0.036B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.035B 0.00
Liminatus Pharma (LIMN) United States $0.032B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.030B 25.00
Iterum Therapeutics (ITRM) Ireland $0.029B 0.00
Scienture Holdings (SCNX) United States $0.026B 0.00
Cosmos Health (COSM) United States $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
SCYNEXIS (SCYX) United States $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.021B 0.00
Vivos Therapeutics (VVOS) United States $0.019B 0.00
Vyome Holdings (HIND) United States $0.019B 0.00
TherapeuticsMD (TXMD) United States $0.019B 0.00
Mannatech (MTEX) United States $0.018B 0.00
Mangoceuticals (MGRX) United States $0.018B 0.00
Heatwurx (PCSA) United States $0.018B 0.00
Natural Alternatives (NAII) United States $0.018B 0.00
CASI Pharmaceuticals (CASI) China $0.017B 0.00
Lipocine (LPCN) United States $0.016B 0.00
Ainos (AIMD) United States $0.015B 0.00
BioLineRx (BLRX) Israel $0.015B 0.00
Traws Pharma (TRAW) United States $0.013B 0.02
Ernexa Therapeutics (ERNA) United States $0.012B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.012B 0.00
BioVie (BIVI) United States $0.011B 0.00
ProPhase Labs (PRPH) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
VYNE Therapeutics (VYNE) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Aptorum Group (APM) United Kingdom $0.008B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.007B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Nuvilex (PMCB) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
CDT Equity (CDT) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Indaptus Therapeutics (INDP) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Indivior (INDV) United States $0.000B 15.85
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00